<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00022412</url>
  </required_header>
  <id_info>
    <org_study_id>2000-595</org_study_id>
    <secondary_id>P30CA014520</secondary_id>
    <secondary_id>WCCC-CO-99802</secondary_id>
    <secondary_id>NCI-N01-CN-95130</secondary_id>
    <secondary_id>WCCC-CO-2000169</secondary_id>
    <secondary_id>NCI-P01-0188</secondary_id>
    <secondary_id>CDR0000068813</secondary_id>
    <secondary_id>CO99802</secondary_id>
    <nct_id>NCT00022412</nct_id>
  </id_info>
  <brief_title>Doxercalciferol Before Surgery in Treating Localized Prostate Cancer</brief_title>
  <official_title>Phase II Open Label, Multi-Center Clinical Trial Of Modulation Of Intermediate Endpoint Biomarkers By 1x-Hydroxyvitamin D2 In Patients With Clinically Localized Prostate Cancer And High Grade PIN</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Doxercalciferol may be an effective way to treat localized prostate cancer before
      surgery.

      PURPOSE: Randomized phase II trial to study the effectiveness of giving doxercalciferol
      before surgery in treating patients who have localized prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine whether doxercalciferol modulates intermediate endpoint biomarkers in the
           development of prostate cancer in patients with localized prostate cancer.

        -  Assess the toxicity of this drug in these patients.

      OUTLINE: This is a randomized, open-label, multicenter study. Patients are randomized to one
      of 2 arms.

        -  Arm I: Patients receive doxercalciferol once daily for 28 days. Patients then undergo
           prostatectomy.

        -  Arm II: Patients undergo observation for 28 days. Patients then undergo prostatectomy.

      PROJECTED ACCRUAL: A total of 60 patients (30 per arm) will be accrued for this study within
      18 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2001</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intermediate endpoint biomarker modulation</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
    <time_frame>30 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Observation, then prostatectomy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Arm 2: Patients undergo observation for 28 days. Patients then undergo prostatectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxercalciferol once daily for 28 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dietary supplement once daily to treat prostate cancer for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>doxercalciferol</intervention_name>
    <description>Arm 1: Patients receive doxercalciferol once daily for 28 days. Patients then undergo prostatectomy.</description>
    <arm_group_label>Doxercalciferol once daily for 28 days</arm_group_label>
    <other_name>Localized adenocarcinoma of the prostate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <description>Procedure: Prostatectomy for prostate cancer</description>
    <arm_group_label>Observation, then prostatectomy</arm_group_label>
    <other_name>Prostatectomy - no dietary supplement</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed localized adenocarcinoma of the prostate

          -  Candidate for prostatectomy

        PATIENT CHARACTERISTICS:

        Age:

          -  21 and over

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  WBC at least 4,000/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Bilirubin no greater than 1.4 mg/dL

          -  AST no greater than 3 times normal

        Renal:

          -  Creatinine no greater than 2.0 mg/dL

          -  Calcium no greater than 10.2 mg/dL

          -  No idiopathic urinary calcium stone disease

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  Not specified

        Endocrine therapy:

          -  No prior hormonal therapy for prostate cancer

          -  No concurrent hormonal therapy, including luteinizing hormone-releasing hormone
             agonists, antiandrogens, glucocorticoids, ketoconazole, finasteride,
             diethylstilbestrol, or progestins

        Radiotherapy:

          -  No prior brachytherapy or external beam radiotherapy for prostate cancer

        Surgery:

          -  See Disease Characteristics

        Other:

          -  At least 7 days since prior vitamin D therapy or calcium supplements

          -  No other concurrent vitamin D analogues or calcium supplements

          -  No concurrent magnesium-containing antacids

          -  No concurrent thiazide-containing diuretics

          -  No concurrent phenytoin, phenobarbital, glutethimide, digoxin, or digitalis
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Wilding, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center at University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James P. Wilmot Cancer Center at University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meriter Hospital</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-6164</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin Cancer Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226-3596</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>October 10, 2016</last_update_submitted>
  <last_update_submitted_qc>October 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage II prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>1 alpha-hydroxyergocalciferol</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

